drugset / Trial / NCT01117623

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

NCT01117623

Phase 1 Completed 86 enrolled Bayer
Non-randomizedParallel-groupOpen-label

Summary

Continuous dosing of BAY73-4506 in patients with advanced cancer

Timeline

Start
2007-02
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Regorafenib Small molecule 20 mg Oral
Subject Regorafenib Small molecule 40 mg Oral
Subject Regorafenib Small molecule 100 mg Oral
Subject Regorafenib Small molecule 120 mg Oral
Subject Regorafenib Small molecule 140 mg Oral

Indications